Evaluation of the BRADA and ABILHAND Questionnaires

University Hospital, Ghent80 enrolled

Overview

This protocol is designed to evaluate the BRADA and ABILHAND questionnaires in rheumatoid arthritis (RA) patients that will be treated with an effective therapy. Patients with moderate to severe RA treated with tocilizumab will be asked to complete the BRADA and ABILHAND questionnaires at screening, baseline, after 12 weeks and after 24 weeks of treatment. All other assessments and questionnaires from daily clinical practice (such as the global assessment of disease activity by the patient, the Health Assessment Questionnaire (HAQ), the SF36 questionnaire, measurement of ESR and CRP and the DAS 28 calculation), will also be used to evaluate these questionnaires.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Rheumatoid Arthritis

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients with moderate to severe RA. * Inadequate response on earlier optimal use of a minimum of two DMARDs (disease modifying anti-rheumatic drugs such as goldsalts, salazopyrine, leflunomide, methotrexate (MTX)) as far as one of the two used DMARDs is MTX that at the exception of a documented intolerance despite the association with folic acid, should have been administered IM or oral during a minimum of 3 months and at a minimal dose of 15mg/week. * DAS 28 score ≥ 5.1 * For whom a drug that is registered for the treatment of moderate to severe RA is commercially available but does not constitute a satisfactory treatment for this patient.

Locations (19)

Jan Palfijn

Merksem, Antwerpen, Belgium

ASZ

Aalst, Belgium

Clinique St. Luc

Bouge, Belgium

CHU Brugmann

Brussels, Belgium

UCL St. Luc

Brussels, Belgium

UZA

Edegem, Belgium

AZ Sint-Lucas

Ghent, Belgium

University Hospital Ghent

Ghent, Belgium

Reuma Instituut

Hasselt, Belgium

AZ Groeninge

Kortrijk, Belgium

...and 9 more locations

Evaluation of the BRADA and ABILHAND Questionnaires

Overview

Conditions

Eligibility

Locations (19)

Outcomes

Primary Outcomes